Browse > Article
http://dx.doi.org/10.5352/JLS.2021.31.11.980

MMP-2 and MMP-9 Inhibitory Effects of Different Solvent Fractions from Corydalis heterocarpa  

Yu, Ga Hyun (Department of Food and Nutrition, College of Medical and Life Sciences, Silla University)
Karadeniz, Fatih (Marine Biotechnology Center for Pharmaceuticals and Foods, Silla University)
Kong, Chang-Suk (Department of Food and Nutrition, College of Medical and Life Sciences, Silla University)
Publication Information
Journal of Life Science / v.31, no.11, 2021 , pp. 980-986 More about this Journal
Abstract
Natural products have always been an attractive source in terms of novel anti-metastatic compounds which can hinder MMP expression and activity. Corydalis heterocarpa is a salt marsh plant found in the seashores throughout Korea. Its yellow flowers and spikes have been an ingredient in folk medicine to treat spasm and contractions. The present study assessed the potential of different solvent-based fractions from the crude extract of Corydalis heterocarpa (CHE), a halophyte with reported bioactivities, to suppress the PMA-induced MMP expression in human fibrosarcoma HT-1080 cells. The solvent fractions which were named after the solvent used for fractionation (n-hexane, 85% aqueous (aq.) methanol (MeOH), n-butanol (BuOH), and H2O were shown to inhibit the both elevated mRNA and protein expression levels of MMP-2 and MMP-9 and simultaneously relieved the suppression on the expression of the endogenous MMP inhibitors TIMP-1 and TIMP-2. Results indicated that the CHE fractions might intervene with the PMA-induced activation of the MAPK signaling which is the upstream activator of MMP overexpression. Among tested samples, 85% aq. MeOH and n-hexane fractions of CHE was determined to be the most active and future studies to isolate the bioactive substances responsible for the regulation of the MMP expression are, therefore, urged. In conclusion, C. heterocarpa was shown to be a potential source of anti-metastatic compounds and n-Hexane and MeOH fractions might yield lead molecules to develop novel MMP inhibitors.
Keywords
Corydalis heterocarpa; MAPK; MMP-2; MMP-9; TIMP;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Liu, X. W., Tang, C. L., Zheng, H., Wu, J. X., Wu, F., Mo, Y. Y., Liu, X., Zhu, H. J., Yin, C. L., Cheng, B., Ruan, J. X., Song, F. M., Chen, Z. N., Song, H., Guo, H. W., Liang, Y. H. and Su, Z. H. 2018. Investigation of the hepatoprotective effect of Corydalis saxicola Bunting on carbon tetrachloride-induced liver fibrosis in rats by H-NMR-based metabonomics and network pharmacology approaches. J. Pharm. Biomed. Anal. 159, 252-261.   DOI
2 Raeeszadeh-Sarmazdeh, M., Do, L. D. and Hritz, B. G. 2020. Metalloproteinases and their inhibitors: Potential for the development of new therapeutics. Cells 9, 1313.   DOI
3 Tombulturk, F. K., Soydas, T., Sarac, E. Y., Tuncdemir, M., Coskunpinar, E., Polat, E., Sirekbasan, S. and Kanigur-Sultuybek, G. 2019. Regulation of MMP 2 and MMP 9 expressions modulated by AP-1 (c-jun) in wound healing: improving role of Lucilia sericata in diabetic rats. Acta Diabetol. 56, 177-186.   DOI
4 Malemud, C. 2006. Matrix metalloproteinases (MMPs) in health and disease: an overview. Front. Biosci. 11, 1696-1701.   DOI
5 Morales-Vasquez, F., Castillo-Sanchez, R., Gomora, M. J., Almaraz, M. A., Pedernera, E., Perez-Montiel, D., Rendon, E., Lopez-Basave, H. N., Roman-Basaure, E., Cuevas-Covarrubias, S., Maldonado-Cubas, J., Villa, A. and Mendez, C. 2020. Expression of metalloproteinases MMP-2 and MMP-9 is associated to the presence of androgen receptor in epithelial ovarian tumors. J. Ovarian Res. 13, 86.   DOI
6 Murphy, G. 2011. Tissue inhibitors of metalloproteinases. Genome Biol. 12, 233.   DOI
7 Bae, M. J., Karadeniz, F., Oh, J. H., Yu, G. H., Jang, M. S., Nam, K. H., Seo, Y. and Kong, C. S. 2017. MMP-inhibitory effects of flavonoid glycosides from edible medicinal halophyte Limonium tetragonum. Evid. Based Complement. Alternat. Med. 2017, 6750274.
8 Barabas, L., Hritz, I., Istvan, G., Tulassay, Z. and Herszenyi, L. 2021. The behavior of MMP-2, MMP-7, MMP-9, and their inhibitors TIMP-1 and TIMP-2 in adenoma-colorectal cancer sequence. Dig. Dis. 39, 217-224.   DOI
9 Gonzalez-Avila, G., Sommer, B., Mendoza-Posada, D. A., Ramos, C., Garcia-Hernandez, A. A. and Falfan-Valencia, R. 2019. Matrix metalloproteinases participation in the metastatic process and their diagnostic and therapeutic applications in cancer. Crit. Rev. Oncol. Hematol. 137, 57-83.   DOI
10 Kajanne, R., Miettinen, P., Mehlem, A., Leivonen, S. K., Birrer, M., Foschi, M., Kahari, V. M. and Leppa, S. 2007. EGF-R regulates MMP function in fibroblasts through MAPK and AP-1 pathways. J. Cell. Physiol. 212, 489-497.   DOI
11 Kumar, G. B., Nair, B. G., Perry, J. J. P. and Martin, D. B. C. 2019. Recent insights into natural product inhibitors of matrix metalloproteinases. Medchemcomm 10, 2024-2037.   DOI
12 Lv, Y., Zhao, X., Zhu, L., Li, S., Xiao, Q., He, W. and Yin, L. 2018. Targeting intracellular MMPs efficiently inhibits tumor metastasis and angiogenesis. Theranostics 8, 2830-2845.   DOI
13 Wu, Z., He, D., Zhao, S. and Wang, H. 2019. IL-17A/IL-17RA promotes invasion and activates MMP-2 and MMP-9 expression via p38 MAPK signaling pathway in non-small cell lung cancer. Mol. Cell. Biochem. 455, 195-206.   DOI
14 Safranek, J., Pesta, M., Holubec, L., Kulda, V., Dreslerova, J., Vrzalova, J., Topolcan, O., Pesek, M., Finek, J. and Treska, V. 2009. Expression of MMP-7, MMP-9, TIMP-1 and TIMP-2 mRNA in lung tissue of patients with non-small cell lung cancer (NSCLC) and benign pulmonary disease. Anticancer Res. 29, 2513-2517.